P H A R M A 1 Therapeutics For Rare Diseases March 2022 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, a law that gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not cor ...

P H A R M A 1 Full Year 2021 Financial Results & Clinical Update March 10, 2022 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, a law that gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2021. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in its Charter) Delaware 42-1491350 (State or other juris ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Rick Hawkins - Chief Executive Officer & Chairman Lori Lawley - Chief Financial Officer & Principal Accounting Officer John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Ed White - H.C. Wainwright Catherine Novack - Jones Research Elemer Piros - RO ...

P H A R M A 1 Therapeutics For Rare Diseases November 2021 Forward Looking Statements 2 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other ...

Call Start: 16:30 January 1, 0000 4:57 PM ET Lumos Pharma, Inc. (NASDAQ:LUMO) Q3 2021 Earnings Conference Call November 3, 2021 16:30 ET Company Participants Lisa Miller - Senior Director of Investor Relations Rick Hawkins - Chief Executive Officer & Chairman Lori Lawley - Chief Financial Officer & Principal Accounting Officer John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partn ...

P H A R M A 1 Therapeutics For Rare Diseases August 2021 Forward Looking Statements 2 | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other juri ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2021 Earnings Conference Call August 5, 2021 11:00 AM ET Company Participants Lisa Miller - Senior Director-IR Rick Hawkins - CEO and Chairman John McKew - President and Chief Scientific Officer David Karpf - Chief Medical Officer Lori Lawley - CFO and Corporate Controller Conference Call Participants Charles Duncan - Cantor Fitzgerald Ed White - H.C. Wainwright Catherine Novack - Jones Trading Operator Good afternoon, ladies and gentlemen, and welcome to Lumos Pharma's S ...